Wall Street analysts expect ImmunoGen, Inc. (NASDAQ:IMGN) to announce earnings of ($0.40) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for ImmunoGen’s earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.44). ImmunoGen posted earnings of ($0.51) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 21.6%. The business is expected to announce its next earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that ImmunoGen will report full year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.40). For the next fiscal year, analysts expect that the firm will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.59) to ($0.89). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for ImmunoGen.

ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.16. The company had revenue of $28.70 million during the quarter, compared to analyst estimates of $16.16 million. The firm’s quarterly revenue was up 45.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.37) EPS.

IMGN has been the topic of a number of recent research reports. Leerink Swann upgraded shares of ImmunoGen from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $3.53 to $3.90 in a report on Wednesday, April 19th. Jefferies Group LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of ImmunoGen in a report on Wednesday, April 12th. William Blair reiterated an “outperform” rating on shares of ImmunoGen in a report on Monday. Cantor Fitzgerald reiterated a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a report on Monday, May 8th. Finally, Zacks Investment Research upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Friday, March 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $5.88.

ImmunoGen (NASDAQ IMGN) opened at 7.22 on Friday. The firm has a 50-day moving average of $5.12 and a 200 day moving average of $3.52. ImmunoGen has a 1-year low of $1.51 and a 1-year high of $7.40. The firm’s market cap is $645.09 million.

Several institutional investors have recently added to or reduced their stakes in IMGN. State Street Corp boosted its position in ImmunoGen by 3.1% in the fourth quarter. State Street Corp now owns 1,526,398 shares of the biotechnology company’s stock valued at $3,115,000 after buying an additional 45,628 shares in the last quarter. Federated Investors Inc. PA boosted its position in ImmunoGen by 69.6% in the fourth quarter. Federated Investors Inc. PA now owns 108,104 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 44,353 shares in the last quarter. Norges Bank purchased a new position in ImmunoGen during the fourth quarter valued at $3,123,000. Teachers Advisors LLC boosted its position in ImmunoGen by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 209,859 shares of the biotechnology company’s stock valued at $428,000 after buying an additional 20,171 shares in the last quarter. Finally, Creative Planning boosted its position in ImmunoGen by 116.4% in the first quarter. Creative Planning now owns 53,444 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 28,744 shares in the last quarter. 73.93% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “ImmunoGen, Inc. (IMGN) Expected to Post Earnings of -$0.40 Per Share” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/06/30/immunogen-inc-imgn-expected-to-post-earnings-of-0-40-per-share.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Get a free copy of the Zacks research report on ImmunoGen (IMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.